Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan + clarithromycin + metronidazole for Helicobacter pylori eradication in chronic kidney disease without dialysis
jRCTs031200239Recruiting
- Sponsor
- Yokohama City University
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of vonoprazan, clarithromycin and metronidazole in Helicobacter pylori infection, sponsored by Yokohama City University. Primary endpoint: Eradication rate (FAS). Started Feb 2021; status: recruiting.
02
Drugs
vonoprazanclarithromycinmetronidazole
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on jRCTs031200239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200239.